Study of I-DXd for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer must be a type called adenocarcinoma (not small cell) and have spread to distant parts of the body (like bones or other organs).
- Your cancer must have worsened while on hormone therapy (ADT) or after having your testicles removed, within the last 6 months before screening.
- You must have already tried 1 or 2 drugs called androgen receptor pathway inhibitors (like enzalutamide or abiraterone) and your cancer still grew after at least 8 weeks of treatment.
- You need to provide a fresh tumor tissue sample from a biopsy of an area not treated with radiation, taken after your last cancer treatment stopped working.
- You cannot have had prior chemotherapy with a taxane drug (like docetaxel) for prostate cancer that has spread and stopped responding to hormone therapy.
- You cannot have a history of a lung condition called interstitial lung disease or pneumonitis that needed steroids, or currently have it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.